OraSure Technologies (OSUR) Stock Price, News & Analysis

Company Overview

Founded in 1988 and headquartered in Bethlehem, Pennsylvania, OraSure Technologies is a leading provider of point-of-care diagnostic and specimen collection devices under the NASDAQ ticker OSUR. The company's core product lines include the OraQuick HIV and HCV rapid antibody tests, which are used by healthcare providers, public health programs and consumers for early detection of infection. OraSure has expanded its point-of-care franchise to encompass other infectious diseases, including COVID-19 rapid antigen and molecular assays, as well as tuberculosis screening solutions.

In addition to its diagnostic offerings, OraSure holds a prominent position in the specimen collection market. The company’s saliva-based oral fluid collection devices, syphilis blood testing kits and stabilization systems for DNA and RNA collection support a wide range of applications—from forensic testing and consumer genomics to pharmaceutical research and microbiome analysis. These devices streamline the sample-collection process by enabling noninvasive, self-collected specimens, facilitating large-scale screening and decentralized testing models.

OraSure Technologies has built a global distribution network spanning more than 100 countries, with sales, R&D and manufacturing facilities in the United States, Europe and Asia. Over the years, the company has forged strategic partnerships with public health agencies, academic institutions and major diagnostic firms to accelerate product innovation and market access. Its collaboration with the U.S. Centers for Disease Control and Prevention (CDC), for example, has helped shape guidelines for HIV self-testing and expand community-based screening initiatives worldwide.

Under the leadership of President and CEO Douglas A. Michels, OraSure continues to invest in research and development to broaden its diagnostic pipeline, advance digital health initiatives and explore novel biomarker technologies. With a focus on improving patient access, delivering accurate results and enabling decentralized testing, the company aims to address unmet needs in infectious-disease diagnostics, genomics and therapeutic monitoring.

Key Stats

• Today's Range: $3.01 to $3.13
• 50-Day Range: $2.43 to $3.08
• 52-Week Range: $2.36 to $4.92
• Volume: 482,244 shs
• Average Volume: 746,210 shs
• Market Capitalization: $226.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

OraSure Technologies Stock Analysis - MarketRank™

OraSure Technologies scored higher than 36% of companies evaluated by MarketBeat, and ranked 699th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

OraSure Technologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

OraSure Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for OraSure Technologies are expected to decrease in the coming year, from ($0.08) to ($0.29) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OraSure Technologies is -7.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OraSure Technologies is -7.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OraSure Technologies has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.41% of the float of OraSure Technologies has been sold short.

Short Interest Ratio / Days to Cover

OraSure Technologies has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in OraSure Technologies has recently increased by 24.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OraSure Technologies does not currently pay a dividend.

Dividend Growth

OraSure Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.09

Percentage of Shares Shorted

4.41% of the float of OraSure Technologies has been sold short.

Short Interest Ratio / Days to Cover

OraSure Technologies has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in OraSure Technologies has recently increased by 24.70%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for OraSure Technologies this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OraSure Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.90% of the stock of OraSure Technologies is held by insiders.

Percentage Held by Institutions

93.50% of the stock of OraSure Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OSUR Stock Analysis - Frequently Asked Questions

How have OSUR shares performed this year?

OraSure Technologies' stock was trading at $3.61 at the start of the year. Since then, OSUR shares have decreased by 16.1% and is now trading at $3.03.

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) announced its quarterly earnings data on Wednesday, November, 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The company's revenue for the quarter was down 55.2% compared to the same quarter last year.
Read the conference call transcript.

Is OraSure Technologies doing a stock buyback?

OraSure Technologies' Board of Directors approved a stock buyback program on Monday, March 24th 2025, which allows the company to buy back $40,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 15.6% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board believes its shares are undervalued.

How do I buy shares of OraSure Technologies?

Shares of OSUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OraSure Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 7/09/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:OSUR
• CIK: 1116463
• Web: www.orasure.com
• Phone: (610) 882-1820
• Fax: 610-882-1830
• Employees: 840
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OraSure Technologies: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: -1.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.50 million
• Net Margins: -19.77%
• Pretax Margin: -17.55%
• Return on Equity: -5.86%
• Return on Assets: -5.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.34
• Quick Ratio: 10.94

Sales & Book Value

• Annual Sales: $185.83 million
• Price / Sales: 1.22
• Cash Flow: $0.04 per share
• Price / Cash Flow: 78.56
• Book Value: $5.50 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 74,800,000
• Free Float: 71,883,000
• Market Cap: $227.02 million
• Optionable: Optionable
• Beta: 0.45